识别可从乳房切除术后放疗获益的T1-2N1M0乳腺癌高危患者:一项双中心回顾性倾向评分匹配研究
该双中心回顾性倾向评分匹配研究纳入408例医学中心1和190例医学中心2的pT1-2N1M0乳腺癌术后患者,整合临床病理、超声和乳腺X线特征构建多模态列线图。列线图在训练队列C-index为0.816(95%CI 0.774-0.859),外部验证队列为0.846(95%CI 0.772-0.920)。高危组PMRT显著改善RFS(训练队列HR=0.392;外部验证队列HR=0.358,均p<0.05),低危组未获益。
要点
- 多模态列线图整合临床病理、超声和乳腺X线特征,用于评估pT1-2N1M0乳腺癌术后PMRT的风险-获益平衡。
- 高危组PMRT显著改善RFS(训练队列HR=0.392;外部验证队列HR=0.358,均p<0.05)。
- 低危组未从PMRT获益(训练队列HR=0.173;外部验证队列HR=0,均p>0.05)。
核心结论
- 多模态列线图可作为临床决策支持工具,帮助临床医生评估PMRT的风险-获益平衡,并可能指导pT1-2N1M0乳腺癌女性的进一步个体化辅助治疗。
研究设计与样本
- 双中心回顾性倾向评分匹配研究,纳入医学中心1的408例(2011年1月至2019年6月)和医学中心2的190例(2017年1月至2019年6月)经病理分期为pT1-2N1M0且接受乳房切除术的乳腺癌患者,术前均有乳腺X线和超声影像;经倾向评分匹配后,采用单因素和多因素Cox回归分析构建多模态列线图。
诊断标准与关键数值
- 多因素分析识别的独立危险因素包括年龄、病理T分期、腋窝淋巴结阳性、脉管侵犯、超声上的微钙化和血流、乳腺X线上的结构扭曲和可疑钙化(均p<0.05);多模态列线图C-index在训练队列为0.816(95%CI 0.774-0.859),在外部验证队列为0.846(95%CI 0.772-0.920);高危组PMRT改善RFS(训练队列HR=0.392;外部验证队列HR=0.358,均p<0.05),低危组未获益(训练队列HR=0.173;外部验证队列HR=0,均p>0.05)。
临床应用与阅片要点
- 作者认为该多模态列线图可作为临床决策支持工具,用于评估PMRT的风险-获益平衡,并可能指导pT1-2N1M0乳腺癌女性的进一步个体化辅助治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To develop a personalized risk stratification nomogram, integrating clinicopathological, sonographic, and mammographic features, to identify high-risk patients who may benefit from postmastectomy radiotherapy (PMRT).
MATERIALS AND METHODS: A retrospective analysis was conducted on 408 patients from Medical Center 1 (January 2011 to June 2019) and 190 patients from Medical Center 2 (January 2017 to June 2019) with pathologically staged pT1-2N1M0 breast cancer following mastectomy, with preoperative mammography (MG) and ultrasound (US) imaging. After propensity score matching (PSM), the multimodal nomogram was developed using univariate and multivariate Cox regression analyses.
RESULTS: With multivariate analysis, independent risk factors were identified, including age, pathologic T stage, positive axillary lymph nodes, lymphovascular invasion, microcalcifications, and vascularity on US, architectural distortion, and suspicious calcifications on MG (all p < 0.05). The C-index for the multimodal nomogram was 0.816 (95% CI: 0.774-0.859) in the training and 0.846 (95% CI: 0.772-0.920) in the external validation cohort, demonstrating superior prognostic accuracy, discriminative ability, and clinical applicability than clinicopathological and imaging-only models. Risk stratification using this nomogram showed that PMRT significantly improved RFS in the high-risk group (training cohort: HR = 0.392; external validation cohort: HR = 0.358, both p < 0.05), while patients in the low-risk group did not derive benefit from PMRT (training cohort: HR = 0.173; external validation cohort: HR = 0, both p > 0.05).
CONCLUSION: This multimodal nomogram served as a clinical decision-support tool for clinicians to assess the risk-benefit balance of PMRT and had potential clinical application to guide further personalized adjuvant therapy for women with pT1-2N1M0 breast cancer.
KEY POINTS: Question Can the multimodal nomogram integrating clinicopathological, ultrasonic, and mammographic parameters identify high-risk pT1-2N1M0 patients who may benefit from postmastectomy radiation therapy? Findings By effectively risk-stratifying, the nomogram identified high-risk patients who derived significant benefit from PMRT while distinguishing low-risk patients who could potentially avoid unnecessary treatment. Clinical relevance The multimodal nomogram served as a clinical decision-support tool for clinicians to optimize personalized adjuvant therapeutic approaches and improve survival outcomes for patients with pT1-2N1M0 breast cancer.
引用
- Xu Z, Zhang Y, Zou Y, et al. Identify high-risk patients of T1-2N1M0 breast cancer who benefit from postmastectomy radiotherapy: a dual-center retrospective propensity score-matched study. Eur Radiol. 2025. PMID: 41139173. doi:10.1007/s00330-025-12091-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。